AG真人官方

Athira Pharma, Inc. (ATHA) has filed a Form 144 indicating the planned sale of 8,526 common shares through broker Morgan Stanley Smith Barney LLC. The proposed transaction represents approximately 0.022 % of the company鈥檚 39.0 million shares outstanding and carries an aggregate market value of $2,502 based on the price at the time of filing. The shares originate from a restricted-stock lapse dated 30 June 2025 and are scheduled to be sold on or after 1 July 2025 on the NASDAQ exchange. No previous insider sales were reported during the last three months, and the filer asserts the standard representation of having no undisclosed adverse information about the company.

The notice is procedural, providing investors with transparency into a forthcoming, modest-size insider disposition. Given the small fraction of total shares and the absence of other material operational or financial disclosures, the filing is unlikely to have a meaningful impact on ATHA鈥檚 share price or fundamentals.

Servotronics, Inc. (SVT) Form 4 鈥� insider disposal related to pending merger

Director Karen L. Howard reported the cash disposal of her entire equity position in Servotronics on 01 July 2025. Two transactions were disclosed:

• 6,465 common shares tendered and exchanged for $47.00 per share under the Agreement and Plan of Merger with TransDigm Inc. (Transaction code 鈥淯鈥�).
• 536 restricted shares that vested upon the change-in-control were simultaneously converted to cash at the same $47.00 consideration (Transaction code 鈥淒鈥�).

Following these actions, the reporting person now holds 0 SVT shares (direct or indirect). The filing confirms that stockholders who validly tendered鈥攐r whose shares were cancelled at closing鈥攚ill receive the all-cash consideration of $47.00, subject to standard tax withholding.

No derivative securities were reported. The Form 4 reinforces that the cash tender offer has progressed to the 鈥淎cceptance Time,鈥� signalling practical completion of the TransDigm acquisition of Servotronics.

Form 144 filing for NVIDIA Corporation (NVDA): A trust named Rosemary and A Brooke Seawell Revocable Trust has filed a Form 144 indicating its intent to dispose of 51,740 common shares of NVIDIA on or about 1 July 2025. The planned sale, to be executed through Rockefeller Capital Management, Two Embarcadero Center, San Francisco, carries an aggregate market value of US$7,999,955.78. The shares represent an immaterial fraction of the issuer鈥檚 reported 24.4 billion shares outstanding.

Background on the shares: The trust originally acquired the stock on 12 Aug 2004 via the exercise of stock options, paid for in cash or check. No gifts or non-cash consideration are noted.

Recent insider activity:

• During the period 20-30 June 2025 the same trust executed seven open-market sales totaling 357,351 shares for combined gross proceeds of roughly US$55.9 million. Individual daily blocks ranged from 50,912 to 55,682 shares, each near the US$8 million mark.

Under Rule 144, the filer certifies that it possesses no undisclosed material adverse information and, if relying on a Rule 10b5-1 plan, that such plan was properly adopted. No plan-adoption date is provided in the filing excerpt.

The notice is routine and does not indicate any changes to NVIDIA鈥檚 operations, strategy or financial outlook. Given NVIDIA鈥檚 large float, the proposed sale is unlikely to have a measurable effect on liquidity or control.

NVIDIA Corp. (NVDA) 鈥� Form 144 filing dated 30 June 2025

An affiliated insider, identified as the Rosemary & A Brooke Seawell Revocable Trust, has filed notice of intent to sell 50,912 common shares of NVIDIA through Rockefeller Capital Management on or after 30 June 2025. The proposed sale carries an aggregate market value of approximately US$8.0 million. These shares were originally acquired on 12 Aug 2004 via stock-option exercise.

The filing also discloses that during the preceding three months the same trust completed six open-market transactions, divesting a combined 320,639 shares for total gross proceeds of roughly US$48 million. All sales were executed on Nasdaq between 20 June and 27 June 2025.

Relative to NVIDIA鈥檚 reported 24.4 billion shares outstanding, the proposed sale represents about 0.0002 % of total shares and is therefore immaterial to capital structure. However, successive insider disposals can influence sentiment, especially amid NVIDIA鈥檚 elevated valuation.

• No reference is made to a Rule 10b5-1 trading plan, although the form provides a placeholder for such disclosure.
• The signer attests to possessing no undisclosed material adverse information, as required by Rule 144.

Key take-away: The notice signals continued insider profit-taking but is unlikely to affect NVIDIA鈥檚 liquidity, earnings, or operating outlook.

Lamb Weston Holdings, Inc. (LW) filed an 8-K announcing a wide-ranging Cooperation Agreement dated 30 Jun 2025 with activist investor JANA Partners and Continental Grain Company.

Board re-composition: The Company will expand its Board from 11 to 13 seats and accept the resignations of Charles A. Blixt, W.G. Jurgensen, Robert A. Niblock and Maria Renna Sharpe (two already effective 29 Jun 2025). Six Agreed Directors will be appointed no later than 11 Jul 2025: Bradley Alford (new non-executive Chairman), Timothy R. McLevish, Scott Ostfeld, Ruth Kimmelshue, Paul Maass and Lawrence Kurzius. Each brings senior leadership or activist experience across food, agribusiness and consumer sectors.

Committee alignment: 鈥� Audit & Finance 鈥� 5 members (incl. McLevish & Maass). 鈥� Compensation & Human Capital 鈥� 6 members (incl. Kimmelshue, Kurzius & Ostfeld). 鈥� Nominating & Governance 鈥� 6 members (incl. Kimmelshue, Kurzius & Ostfeld).

Shareholder obligations & standstill: JANA and Continental Grain agree to (1) vote in line with Board recommendations (with limited proxy-advisor exceptions), (2) maintain a 鈮�1.5 % net long position to keep board representation, (3) adhere to mutual non-disparagement, and (4) observe a standstill that runs until the earlier of 30 days before the 2026 advance-notice window or 28 Apr 2026.

Replacement rights: If any of the designated directors departs before the Termination Date, JANA, Continental Grain or both (depending on the seat) may name replacements, subject to customary independence and suitability criteria.

Rationale & disclosure: While no financial metrics were provided, the agreement averts a potential proxy contest, refreshes governance with seasoned industry leaders, and signals collaboration between management and key shareholders. The Company issued a press release (Exhibit 99.1) and attached the full Cooperation Agreement (Exhibit 10.1).

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) filed a Form 8-K dated 24 June 2025.

Item 1.01 鈥� Material Agreement: The company executed Amendment No. 1 to its existing license agreement with Yuhan Corporation, effective 11 June 2025 and formally signed on 24 June. The amendment is connected to a 17 June 2025 term sheet with Intact Therapeutics, suggesting a coordinated expansion of collaborative development efforts. Specific financial terms, milestone obligations or royalty adjustments were not disclosed.

Item 5.07 鈥� Submission of Matters to a Vote of Security Holders: The 30 June 2025 Annual Shareholder Meeting in Hanover, MD lacked a quorum and was adjourned without conducting business. The meeting will reconvene on 30 July 2025 at 1:00 p.m. EDT. The record date remains 1 May 2025; previously submitted proxies stay valid and proposals are unchanged.

Exhibits: 10.1 鈥� Amendment No. 1 to the Yuhan License Agreement; 104 鈥� Cover Page Inline XBRL data.

The filing signals ongoing partnering activity that could enhance the company鈥檚 pipeline while underscoring a temporary governance setback due to insufficient shareholder participation.

Form 4 filing overview: Director Dawn E. Hudson reported the receipt of 1,799 shares of NVIDIA common stock on 06/26/2025. The shares are in the form of restricted stock units (RSUs) that were granted at no cash cost as part of the company鈥檚 annual equity award for board service. According to the accompanying footnote, the RSUs will vest 50% on 11/19/2025 and 50% on 05/20/2026; all units vest immediately if the director鈥檚 service ends due to death.

Following the grant, Hudson鈥檚 directly held position rises to 458,887 shares. There were no disposals or sales reported in this filing, and no derivative securities were listed. The transaction was coded 鈥淎鈥� (acquisition) and carries a price of $0, confirming it is purely a compensatory award rather than an open-market purchase.

Given NVIDIA鈥檚 market capitalization, the incremental 1,799 shares represent an immaterial addition from a corporate-level perspective but continue to align the director鈥檚 incentives with shareholder value. No other directors or insiders were included in this filing, and no amendments to prior reports were noted.

Bridgeline Digital, Inc. (BLIN) 鈥� Form 4 insider transaction

Director Brandon Ross filed a Form 4 reporting two transactions dated 06/26/2025:

• Acquisition (Code A): 20,133 shares of common stock were awarded at $0.00 per share, increasing his stake.
• Disposition (Code F): 6,785 shares were withheld/disposed of at $1.51 per share to satisfy exercise-price or tax obligations.

The net result is a 13,348-share increase, bringing Ross鈥檚 direct ownership to 63,348 shares. No derivative securities were reported.

Royal Bank of Canada (RY) has filed a preliminary 424(b)(2) pricing supplement for three separate Capped Enhanced Return Buffer Notes maturing 4 August 2027. Each note is linked to a single equity index鈥擭asdaq-100 (NDX), Russell 2000 (RTY) or S&P 500 (SPX)鈥攁nd will be issued in $1,000 denominations on 5 August 2025.

Upside mechanics. If the Final Underlier Value exceeds the Initial Underlier Value, investors receive 150 % of the index return, capped at a Maximum Return set on the trade date (indicative ranges: NDX 24.5-26.5 %, RTY 28-30 %, SPX 20-22 %).

Downside mechanics. A 10 % buffer protects principal as long as the index does not lose more than 10 %. Below that threshold, principal is reduced point-for-point beyond the 10 % loss. Example: a 50 % index decline produces a 40 % note loss ($600 redemption).

Key terms.

• Participation Rate: 150 % (subject to cap)
• Buffer Value: 90 % of initial index level
• Trade Date: 31 Jul 2025  |  Valuation Date: 30 Jul 2027
• Maturity: 4 Aug 2027 (2-year term)
• Price to public: 100 % of face; underwriting discount 1 % (dealer concessions up to $10 per $1,000)
• Initial estimated value: $928-$979 (i.e., 92.8-97.9 % of face), below issue price

Risk highlights. The notes pay no coupons, have limited upside due to the cap, and expose investors to 1-for-1 downside beyond the 10 % buffer. They are senior unsecured obligations of Royal Bank of Canada鈥攑ayments depend on the bank鈥檚 credit. The securities are intended to be held to maturity; no exchange listing is planned and secondary liquidity is expected to be thin, with bid-ask spreads and dealer mark-downs likely. The issuer鈥檚 initial estimated value鈥攃alculated using RBC鈥檚 internal funding rate鈥攚ill be lower than the offering price, creating an immediate economic cost to the investor. U.S. tax treatment is uncertain; RBC expects the notes to be treated as prepaid financial contracts.

Investors seeking enhanced, but capped, equity exposure with partial downside protection may find the structure useful; however, the product鈥檚 risk/return trade-off, illiquidity, and issuer credit considerations must be carefully weighed.